Videos

A discussion on the development of targeted therapies for the management of advanced cholangiocarcinoma, with consideration of multiple ongoing trials with notable outcomes.

Experts in gynecological oncology review 3 clinical cases and best practices for various patients with newly diagnosed and recurrent ovarian cancer.

Petros Grivas, MD, PhD, discusses the JAVELIN Bladder 100 trial of maintenance avelumab plus best supportive care versus best supportive care alone after platinum-based first-line chemotherapy in patients with advanced urothelial carcinoma.

Lucy Gilbert, MD, MSc, discusses the findings from a phase 1b trial in which mirvetuximab soravtansine was combined with bevacizumab in recurrent, high-grade epithelial ovarian cancer regardless of platinum sensitivity.

Pierre Gholam, MD, provides insight on the case of a 61-year-old man with stage 4 hepatocellular carcinoma and evaluates current treatment options on TKIs.

Axel Hauschild, MD, PhD, discusses the key findings from the phase 3 COMBI-AD clinical trial, which demonstrated sustained long-term relapse-free survival benefit with the combination of dabrafenib and trametinib compared with placebo in patients with resected, stage III BRAF V600E/K-mutated melanoma.

Mikkael Sekeres, MD, discusses a phase 2 study of pevonedistat plus azacitidine versus azacitadine monotherapy in patients with higher-risk myelodysplastic syndromes /chronic myelomonocytic leukemia or low-blast acute myelogenous leukemia.

Julia K. Rotow, MD, discusses the excitement of EGFR tyrosine kinase inhibitors for the treatment of patients with EGFR-mutant lung cancers.